Overview

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

Status:
Enrolling by invitation

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

Phase 1, multicenter, open-label, 2-part, single- and multiple-dose study designed to assess the effect of hepatic insufficiency on the PK of aramchol

Phase:

Phase 1

Details

Lead Sponsor:

Galmed Research and Development, Ltd.

Treatments:

Cholic Acids